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295 CF patients diagnosed in adulthood: spectrum of referral source
N. Hunt1, G.H. Jones1, E. Phitidis1, M. Murthy1, J. Greenwood1, M. Ledson1,
M. Walshaw1. 1Liverpool Heart and Chest Hospital, Respiratory Medicine,
Liverpool, United Kingdom
Objectives: Although the vast majority of individuals with CF are diagnosed under
the age of 3 years, increased awareness of the condition amongst adult clinicians
means that up to 12% of diagnoses are now made in adulthood (UK CF Registry
2012). As speciﬁc CF treatment is linked to improved outcomes, we looked at the
characteristics of patients attending our centre who were diagnosed in adulthood.
Methods: All 32 patients diagnosed in adulthood (deﬁned as age >17 years, 11.2%
of the total) were identiﬁed. The referral source and reason were studied: any
radiological ﬁndings at referral were used to aid this.
Results: The median diagnosis age was 30 years (range 19−60). Twenty-two
patients (69%) were referred from general chest clinics and the remainder from
surgical, fertility and genetics services. The commonest referral reason was recur-
rent lower respiratory infection (11, 34%), followed by a paediatric family history
(5, 16%). 2 patients (6%) were referred from fertility services with azoospermia.
24 (75%) had undergone HRCT at referral (18 from chest clinics): 18 (82%) had
bronchiectasis (7 severe widespread, 6 mild widespread, 3 lower lobe, 2 upper lobe)
and 1 patient had bronchial wall thickening.
Conclusion: CF can be diagnosed at any age and in a number of different
specialties. Though the majority were referred by respiratory clinicians, some
patients were diagnosed in surgery or fertility clinics illustrating the increasing
awareness of adult CF as a clinical entity. As expected those referred from non-
respiratory sources were more likely to have a normal HRCT. Improving links
between CF centres and other specialities may help the diagnosis rate in the adult
population.
296 Adult CF diagnosis − missed childhood opportunities or
forme fruste disease?
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Objectives: Although the majority of the CF population is diagnosed in childhood,
up to 12% only appear in adulthood (UK CF Registry 2012). To study the reasons
for this we compared the characteristics of our patients diagnosed in adulthood
(AD) with the general adult CF population (GP).
Methods:We looked at all 32 patients diagnosed in adulthood (deﬁned as >17 years
of age) attending our large adult centre (11.2% of the total). We reviewed their
phenotype and genotype and compared their cohort characteristics with those given
in the UK CF Registry Report 2012 where possible.
Results: Median age at diagnosis was 30 years (range 19−60 years) and 13 (41%)









Genotype DF508/DF508 12.5 51.7 Sputum culture Chronic Psa 28.1 54.3
DF508/other 62.5 39 S. aureus 28.1 24
Gene/− 43.7 10.7 MRSA 6.2 4
−/− or no DF508 25 9.4 Burkholderia sp. 3.1 5.1
CFRD 32 30 NTM 12.5 7.3
CFRLD 3.1 18.1 Unknown 6.2
ABPA 18.8 12.5 Other 31
Employment 75 70 Pancreatic
sufﬁcient
31 20
Conclusion: Our CF patients diagnosed in adulthood tend to have a less severe
disease phenotype compared to the general CF population. In keeping with this
fewer were pancreatic insufﬁcient or had liver disease. Nevertheless the lung
pathogen load was similar although proportions of infecting organisms differed.
These results suggest that most late diagnoses are a result of less severe disease:
newborn screening programs may bring these forme fruste individuals to light
earlier, possibly improving their prognosis.
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Objectives: Cystic Fibrosis (CF) population in Israel consists of 600 patients from
whom 150 are Israeli Arabs (A-CF) who may differ from the Jewish population
(J-CF) in genetics, demographics, economic status, cultural and religious aspects.
The aim of our work was to characterize differences in CF between both populations.
Methods: Data from medical records was retrospectively collected form 147
A-CF and compared to 64 age, sex and genetic mutation matched and 104 non-
matched J-CF.
Results: Homozygotes or compound heterozygotes to 2 mild mutations were
more common in A-CF (10.2% vs. 4.8%; p< 0.05), while 1 severe mutation
was more common in J-CF (22.1% vs. 6.1%; p< 0.05). Airway colonization with
Pseudomonas aeruginosa was similar between A-CF and J-CF but A-CF had less
colonization with Methicillin-resistant Staphylococcus aureus and Mycobacterium
abscessus (1.4% vs. 8.6% and 2.0% vs. 30.7%; p< 0.001). A-CF had less CF related
conditions compared to J-CF (77.4% vs. 87.5; p< 0.05) however, failure to thrive
was more prevalent in A-CF (26% vs. 10.6%; p< 0.05). In longitudinal follow up
of pulmonary functions in the last 10 years A-CF showed a trend of higher FEV1
values.
Conclusion: Israeli Arab patients seem to have a less severe course of disease
compared to Jewish patients as reﬂected by less colonization of airways, less CF-
related conditions and better lung functions despite a worse nutritional state. This
may be attributed to differences in genetics therefore a screening project is now
being implemented.
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Objectives: To identify clinical and genetic features of CF in Russia by establishing the CF patients
Registry (RCFpR).
Methods: In 2011 there was initiated a project to establish and maintain the new version of RCFpR
with the inclusion of detailed data on the genetic, diagnostic, clinical and therapeutic information
comparable with the ECFS Patient Registry. RCFpR included data from 17 regions, representing a
total of almost 54 million of the Russian population (37.4% of the total population). RCFpR included
1015 (544 male) CF patients.
Results: The main data: average age of CF patients was 11.5±8.8 (min 0.03, max 44.2), the proportion
of patients older 18 years was 24.0%, median age at diagnosis 1 year (min 0, max 41.0). Frequency
of F508del was 52.2%, CFTR dele2,3 6.3%, E92K 2.5%. FEV1 64.3±23.5%, FVC 72.1±24.3%.
91.9% of patients were treated with dornase alpha, 60% with bronchodilators, 18.4% inhaled
steroids, 8.2% hypertonic saline, 48.5% intravenous antibiotics, 46.3% oral antibiotics, 39.6% inhaled
antibiotics, 92.6% pancreatic enzymes, 91.5% UDCA, 5.8% systemic steroids, 62.0% fat-soluble
vitamins. Only 55.8% did physiotherapy, 5.8% were on oxygen therapy. Chronic infection with
P. aeruginosa was present in 30.4% (intermittent 9.3%) of patients, with S. aureus in 55.3%,
B. cepacia in 6.5% and S. maltophilia in 3.1%. CF complications: diabetes 3.1%, liver disease 28.5%,
electrolyte disorders 2.8%, pneumothorax 1.5%. During this period 15 patients died, mean age at death
16.0±12.8 years (min 0.3, max 36.8).
Conclusion: The establishing of the RCFpR will facilitate a long-term planning of CF service
including ﬁnancial costs in Russia.
